Group 1: Company Strategy - The company's current strategic direction is driven by a "full-package strategy + CVC ecological investment" model, aiming to strengthen its full-chain service capabilities from PCC to IND to NDA while expanding service coverage and technical depth [2] - The company has participated in projects such as the Shenzhen Luohu Donghai Wisdom Pharmaceutical Industry Investment Fund, leveraging its "chain master" role to integrate industry resources and achieve win-win development [3] Group 2: Customer Structure - The customer base is diverse, including multinational pharmaceutical companies (MNCs), biotech firms, and research institutions, with mid-sized biotech companies and MNCs forming the core customer group [4] - These key customers are characterized by stable development, ample funding, and controllable project advancement, providing a solid foundation for the company's ongoing business growth [4] Group 3: AI Technology Integration - The company has over 20 years of R&D experience, utilizing AI technology to enhance research efficiency, shorten development cycles, and reduce the number of candidate compounds, thereby lowering overall R&D costs [4] - A systematic approach is being taken to build a "scientific research intelligent hub platform," improving efficiency in daily operations and applying AI in critical areas such as antibody discovery and drug property prediction [5] Group 4: Nucleic Acid Field Development - The company has established a comprehensive innovative platform covering large and small nucleic acids, with a complete technical system that includes chemical modifications and innovative monomers [6] - Collaborations with companies like Saint Nor Pharmaceutical and Haiyou Biology have been initiated to strengthen capabilities in the nucleic acid sector [7] Group 5: Performance Goals - The three-year stock incentive performance targets have a gradually increasing range due to the initial phase of strategic execution, focusing on overcoming current challenges and key tasks such as the CVC industry fund layout for 2024-2025 [7] - The strategic effects are expected to gradually manifest from 2026 to 2027, leading to an accelerated release cycle of full-package orders, hence the broader performance target range [7]